Pure seminoma: A review and update

Radiation Oncology

Table 2 Relapses and survival in randomized controlled trials in stage 1 seminoma

Reference/No. of patients	Treatment	Total relapses	No. pelvic relapses	Relapse-free survival	Other
[44] n = 625	20 Gy RT (n = 313)	11	3	At 2 years: 97%	8/9 pelvic relapses occurred in the PA RT field group
	30 Gy RT (n = 312)	10	6	At 5 years: 97%*
[43] n = 478	DL RT (n = 242)	9	0	At 3 years: 96.6% At 5 years: 96.2%*	3-years OS: 100%
	PA RT (n = 236)	9	4	At 3 years: 96% At 5 years: 96.1%*	3-years OS: 99.3%
[18, 58] n = 1477	RT: PA or DL, 20 or 30 Gy (n = 904)	36	10	At 3 years: 95.9% At 5 years: 96%*	- All pelvic relapses occurred in the PA RT group - 74% of relapses in the carboplatin group occurred in the PA nodes
	1 cycle carboplatin (n = 573)	29	0	At 3 years: 94.8% At 5 years: 94.7%*

RT: radiation therapy; DL: Dog-Leg; PA: para-aortic; OS: overall survival;* data retrieved in update.

ISSN: 1748-717X